ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A randomised, open-label stud y of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints
EudraCT number 2005-000657-29
Protocol number CSTI571K2301
Sponsor Novartis Pharma Services AG, Basel, Switzerland
Indications Hemato-oncology
Diagnosis chronic myeloid leukamia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2006
Date of approval by Institute (SÚKL) 10.05.2006
Date of approval by EC 04.05.2006
Date of initiation CT in ČR 12.10.2006
Date of ending CT in ČR 08.04.2010
Sites Hematoonkologické oddělení, Fakultní nemocnice Plzeň, Alej Svobody 80, 304 60 PLZEŇ
Hematoonkologické oddělení, Fakultní nemocnice Olomouc, I. P. Pavlova 6, 775 20 OLOMOUC

‹‹ Back to list